Overview

A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia

Status:
Terminated
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as evacetrapib in Japanese participants with primary hypercholesterolemia. The double blind treatment period will last for 12 weeks and the open-label extension period will last for an additional 40 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Evacetrapib